特利加压素在重症监护室住院的肝肾综合征-急性肾损伤患者中的作用:CONFIRM试验的子研究
该研究为CONFIRM III期试验的回顾性子分析,纳入ICU住院的成人HRS-AKI患者45例(特利加压素31/199[16%],安慰剂14/101[14%]),随机按2:1接受特利加压素或安慰剂最长14天。ICU存活患者中,特利加压素组中位ICU住院时间显著短于安慰剂组(4 vs 11天;p<0.001),肾功能较基线改善更显著(-0.7 vs +0.2 mg/dL;p=0.001),考虑治疗与入ICU日交互作用后仍显著(-0.7 vs +0.9 mg/dL;p<0.001)。至第90天累积RRT需求特利加压素组低于安慰剂组(10/31[32%] vs 8/14[57%];p=0.12),但未达统计学显著。13例肝移植患者中,安慰剂组5/5(100%)需RRT,特利加压素组5/8(63%)。
要点
- ICU住院的HRS-AKI患者中,特利加压素组ICU存活者中位ICU住院时间4天,显著短于安慰剂组11天(p<0.001)。
- 特利加压素组肾功能较基线改善-0.7 mg/dL,安慰剂组为+0.2 mg/dL(p=0.001);考虑治疗与入ICU日交互作用后为-0.7 vs +0.9 mg/dL(p<0.001)。
- 至第90天累积RRT需求特利加压素组32%(10/31)vs 安慰剂组57%(8/14),p=0.12,未达统计学显著。
- 13例肝移植患者中,安慰剂组5/5(100%)至第90天需RRT,特利加压素组5/8(63%)。
- CONFIRM试验300例HRS-AKI患者中仅45例在ICU治疗(特利加压素31/199[16%],安慰剂14/101[14%])。
适用人群与场景
- CONFIRM研究中因HRS-AKI入住ICU的成人患者,共45例(特利加压素31/199[16%],安慰剂14/101[14%])。
- 两组入ICU时基线人口学特征及肝功能障碍严重程度相似。
处置流程与药物剂量
- 患者按2:1比例随机接受特利加压素或安慰剂,最长治疗14天。
研究设计与关键结果
- 研究类型:III期CONFIRM研究的回顾性子分析;样本量:45例ICU住院的HRS-AKI患者(特利加压素31例,安慰剂14例);干预:特利加压素 vs 安慰剂,2:1随机,最长14天。
- 主要终点:ICU存活患者中,特利加压素组中位ICU住院时间4天 vs 安慰剂组11天(p<0.001)。
- 肾功能较基线变化:特利加压素组-0.7 mg/dL vs 安慰剂组+0.2 mg/dL(p=0.001);考虑治疗与入ICU日交互作用后为-0.7 vs +0.9 mg/dL(p<0.001)。
- 至第90天累积RRT需求:特利加压素组10/31(32%)vs 安慰剂组8/14(57%),p=0.12,未达统计学显著。
- 13例肝移植患者中,至第90天需RRT者安慰剂组5/5(100%)vs 特利加压素组5/8(63%)。
证据类型、等级与局限
- 证据类型:III期随机对照试验CONFIRM的回顾性子分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在ICU住院的HRS-AKI成人患者中,特利加压素组较安慰剂组更可能实现肾功能改善(基于治疗结束时血清肌酐变化),且ICU住院时间显著更短。
- 至第90天累积RRT需求在特利加压素组数值上低于安慰剂组(32% vs 57%),但差异未达统计学显著(p=0.12)。
指南或共识出处
- CONFIRM试验
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: This study assessed the potential advantages of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) with terlipressin versus placebo in the ICU setting.
DESIGN: Patients were randomly assigned in a 2:1 ratio to receive terlipressin or placebo for up to 14 days.
SETTING: A retrospective analysis of data from the phase III CONFIRM study.
PARTICIPANTS: Adult patients with HRS-AKI admitted to the ICU.
MAIN OUTCOMES AND MEASURES: In this substudy, we evaluated outcomes of the ICU stay and the need for organ support, including renal replacement therapy (RRT).
RESULTS: Among 300 patients with HRS-AKI from the CONFIRM study, 45 were treated in the ICU (terlipressin, 31/199 [16%]; placebo, 14/101 [14%]). On ICU admission, baseline demographics were similar across treatment arms, including severity of liver dysfunction. Among patients alive at the end of the ICU stay, those randomized to terlipressin had a significantly shorter median length of ICU stay than placebo (4 vs 11 d; p < 0.001). Terlipressin-treated patients had a significantly larger improvement in renal function from baseline versus placebo (-0.7 vs +0.2 mg/dL; p = 0.001), including when accounting for the interaction between treatment and day-of-patient-admission to the ICU (-0.7 vs +0.9 mg/dL; p < 0.001). Cumulative requirement for RRT through day 90 was improved in the terlipressin arm versus placebo (10/31 [32%] vs 8/14 [57%]; p = 0.12), although not significantly. Of 13 patients who received a liver transplant, five out of five (100%) in the placebo arm needed RRT through day 90 versus five out of eight (63%) in the terlipressin arm.
CONCLUSIONS: In this subanalysis of CONFIRM, patients admitted to the ICU with HRS-AKI who received terlipressin were more likely to achieve renal function improvement, based on serum creatinine changes by the end of treatment, and had significantly shorter lengths of ICU stay than patients randomized to the placebo arm.
参考来源
- Karvellas CJ, Subramanian R, Olson JC, et al. Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial. Crit Care Explor. 2023. PMID: 37007903. doi:10.1097/CCE.0000000000000890
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。